42 32

Cited 5 times in

SMPDL3b modulates insulin receptor signaling in diabetic kidney disease

Authors
 A. Mitrofanova  ;  S. K. Mallela  ;  G. M. Ducasa  ;  T. H. Yoo  ;  E. Rosenfeld-Gur  ;  I. D. Zelnik  ;  J. Molina  ;  J. Varona Santos  ;  M. Ge  ;  A. Sloan  ;  J. J. Kim  ;  C. Pedigo  ;  J. Bryn  ;  I. Volosenco  ;  C. Faul  ;  Y. H. Zeidan  ;  C. Garcia Hernandez  ;  A. J. Mendez  ;  I. Leibiger  ;  G. W. Burke  ;  A. H. Futerman  ;  L. Barisoni  ;  Y. Ishimoto  ;  R. Inagi  ;  S. Merscher  ;  A. Fornoni 
Citation
 NATURE COMMUNICATIONS, Vol.10(1) : 2692, 2019 
Journal Title
 NATURE COMMUNICATIONS 
Issue Date
2019
MeSH
Animals ; Antigens, CD/metabolism* ; Caveolin 1/metabolism ; Cell Line ; Cell Membrane/metabolism ; Ceramides/metabolism ; Ceramides/therapeutic use ; Cyclic Nucleotide Phosphodiesterases, Type 3/genetics ; Cyclic Nucleotide Phosphodiesterases, Type 3/metabolism* ; Diabetic Nephropathies/drug therapy ; Diabetic Nephropathies/pathology* ; Disease Models, Animal ; Female ; Humans ; Insulin/metabolism* ; Male ; Mice ; Mice, Knockout ; Podocytes/cytology ; Podocytes/metabolism ; Protein Isoforms/metabolism ; Receptor, Insulin/metabolism* ; Signal Transduction ; Sphingomyelin Phosphodiesterase/metabolism* ; Treatment Outcome
Abstract
Sphingomyelin phosphodiesterase acid-like 3b (SMPDL3b) is a lipid raft enzyme that regulates plasma membrane (PM) fluidity. Here we report that SMPDL3b excess, as observed in podocytes in diabetic kidney disease (DKD), impairs insulin receptor isoform B-dependent pro-survival insulin signaling by interfering with insulin receptor isoforms binding to caveolin-1 in the PM. SMPDL3b excess affects the production of active sphingolipids resulting in decreased ceramide-1-phosphate (C1P) content as observed in human podocytes in vitro and in kidney cortexes of diabetic db/db mice in vivo. Podocyte-specific Smpdl3b deficiency in db/db mice is sufficient to restore kidney cortex C1P content and to protect from DKD. Exogenous administration of C1P restores IR signaling in vitro and prevents established DKD progression in vivo. Taken together, we identify SMPDL3b as a modulator of insulin signaling and demonstrate that supplementation with exogenous C1P may represent a lipid therapeutic strategy to treat diabetic complications such as DKD.
Files in This Item:
T201904434.pdf Download
DOI
10.1038/s41467-019-10584-4
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Yoo, Tae Hyun(유태현) ORCID logo https://orcid.org/0000-0002-9183-4507
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/173285
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse